TrialGynecologic oncology2015

A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.

David Bender et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.